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It has been shown that stem cell transplantation can regenerate periodontal tissue, and several clinical trials involving transplan-
tation of stem cells into human patients have already begun or are in preparation. However, stem cell transplantation therapy is
a new technology, and the events following transplantation are poorly understood. Several studies have reported side eﬀects and
potentialrisksassociatedwithstemcelltransplantationtherapy.Toprotectpatientsfromsuchrisks,governmentshaveplacedregu-
lations on stem cell transplantation therapies. It is important for the clinicians to understand the relevant risks and governmental
regulations. This paper describes the ongoing clinical studies, basic research, risks, and governmental controls related to stem cell
transplantation therapy. Then, one clinical study is introduced as an example of a government-approved periodontal cell trans-
plantation therapy.
1.Introduction
Since the 1980s, periodontal ligament cells have been consid-
ered a reliable source for periodontal regeneration. Nyman
et al. reported that periodontal ligament (PDL) tissue poss-
esses periodontal regenerative properties [1]. Based on this
regenerative concept, several procedures have been intro-
duced for the selective proliferation of PDL stem cells, such
as guided tissue regeneration and enamel matrix derivative
[2]. However, the desired regenerative outcomes have not
been attained, especially for patients with severe periodontal
defects. Experimental approaches to overcome the limita-
tions of existing therapies have included the ex vivo expan-
sion of stem cells derived from PDL, bone marrow, adipose
tissue, and alveolar periosteum for transplantation as stem
cell replacement therapy in animal studies. These studies
have indicated that the transplantation of stem cells can be
an eﬀective treatment for periodontal defects [2]. As a con-
sequenceofthesesuccessfulanimalstudies,theclinicalappli-
cation of stem cells for the regeneration of periodontal tissue
hasbegun.However,theeﬃcacyandsafetyofsuchcell-based
therapies have not been fully evaluated, and the risks of stem
celltherapieshavebeenunderscoredbyseveralcliniciansand
researchers. In this paper, we ﬁrst review the current research
targeting cell-based therapies for periodontal regeneration
and then discuss the risks and governmental controls of
stem cell transplantation therapy. Last, we will introduce our
ongoing clinical study that was approved by the regulatory
authority of the Japanese government.
2. CurrentProgress in PeriodontalCell
Transplantation Therapy
2.1. Periodontal Ligament-Derived Mesenchymal Stem Cells
(PDL-MSCs). Previous studies that reported the regenera-
tive properties of PDL using animal models indicated the
existence of stem cells in PDL tissue [3, 4]. Liu et al. reported
that autologous PDL-MSCs enhanced regeneration of peri-
odontal tissue, including alveolar bone, cementum and PDL
in a minipig [5]. Feng et al. transplanted autologous PDL
progenitors to three patients who suﬀered from periodontal
disease.Theresultsshowedperiodontalregenerationwithno
adverse eﬀect [6]. Tissue engineering techniques have been2 International Journal of Dentistry
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Figure 1: Periodontal tissue regeneration using PDL cell sheets. (a) Sheets of polyglycolic acid (arrowhead) with or without the cell sheets
were applied onto the root surfaces of canine mandibular premolars. (b) Bone defects were ﬁlled with β-TCP. (c, e) Thick, newly formed
cementum (arrow) and dense collagen ﬁbres were observed in the PDL of the PDL sheet-transplanted group. (d, f) The immunohistochemi-
caldetectionofneuroﬁlamentproteinrevealedthatnewlyformednerveﬁbreswereonlyobservedinthegroupgiventhePDLsheets(arrow).
Scale bars: 100μm in (c) and (e); 50μm in (d) and (f). B: newly formed bone, P: periodontal ligament, and D: root dentin. Modiﬁed from
[13] with permission.
applied to improve these cell-based therapies. Okano et al.
developed a temperature-responsive cell culture technique
to permit the harvest of adherent cultured cells by simply
lowering the temperature [7, 8]. Our group produced PDL-
derived cell sheets using this temperature-responsive culture
dishandfoundthatthecellsheetshadapotentialtopromote
regeneration of periodontal tissue, which was composed of
bone, cementum, and PDL, in vivo (Figure 1)[ 9–12].
Allogeneic transplantation of PDL-MSCs into bone
defects in minipigs has been shown to result in periodontal
regeneration without signiﬁcant immunological rejection
[5]. It has also been shown that porcine PDL-MSCs possess
a low immunogenicity and immunosuppressive function
[14]. These data could shed light on the potential of allo-
geneic transplantations using PDL-MSCs at the clinical level
and, thus, broaden the range of opportunities for cell trans-
plantation therapy.
2.2. Periosteal Cells. Periosteal cells have been reported to be
a potential source of cells for the regeneration of periodontal
tissue [15, 16]. Recently, Mizuno et al. reported that cultured
autologous periosteal cell membranes induced regeneration
of periodontal tissues including bone, cementum, and perio-
dontal ligament in a canine model of a class III furcation
defect [17]. Following the results of these studies, clinical
trials for cell transplantation therapy using periosteal cells
were conducted. Human periosteal cell sheets with platelet-
richplasma(PRP)andhydroxyapatite(HA)weretransplant-
ed into 30 patients who suﬀered from chronic periodontitis,
and this treatment was found to enhance periodontal regen-
eration [18].
2.3. Bone-Marrow-Derived Mesenchymal Stem Cells (BM-
MSCs). Bone-marrow-derived mesenchymal stem cells
(BM-MSCs) have the potential to diﬀerentiate into various
types of tissue, including bone, cartilage, adipose, muscle,
and periodontal tissue [19–22]. Recent in vivo studies have
shown that BM-MSCs could induce periodontal regener-
ation [21, 23]. Clinical trials using BM-MSCs with PRP have
also been conducted, and the results indicated that per-
iodontal regeneration could be induced by this approach as
well [24].
2.4. Adipose-Derived Stem Cells (ADSCs). Adipose-derived
stemcells(ADSCs)areausefulsourceforcelltransplantation
therapy because this tissue is abundant and easy to obtain
compared with other sources. ADSCs have been shown to be
capable of diﬀerentiating into various tissue types [26–29]. It
is reported that ADSCs mixed with PRP had the potential to
regenerate periodontal defects in vivo [30–32], which sup-
ports the use of ADSCs in cell transplantation therapy for
periodontal regeneration.
2.5. Gingival Fibroblast. To recover gingival recession, a cell
transplantation therapy using gingival ﬁbroblasts has been
developed. For this technique, gingival ﬁbroblast sheets
were obtained by culturing gingival ﬁbroblasts on collagen
sponges [33]. The autologous gingival ﬁbroblast sheets were
then transplanted to 14 sites in 4 patients suﬀering from
periodontal disease in order to achieve root coverage. The
results demonstrated regeneration of gingival tissue and
suggested that gingival ﬁbroblasts could be readily harvested
and prepared for transplantation [34].
2.6. ES/iPS Cells. Because embryonic stem (ES) cells and
induced pluripotent (iPS) cells can diﬀerentiate into all types
of somatic cells, so-called pluripotency, they are thought to
be the ultimate cellular source for regenerative therapies.
Recently, clinical trials using ES cells have begun in the Uni-
ted States. However, tumorigenesis is a common concernInternational Journal of Dentistry 3
with this application of ES/iPS cells. Thus, it is highly desired
to achieve commitment of the ES/iPS cells to a diﬀerentiat-
ed state prior to transfer. Tada et al. demonstrated the dif-
ferentiation of ES/iPS cells into a mesodermal lineage [35]
and Duann et al. demonstrated alveolar bone regeneration
by iPS cells in an animal model [36]. Furthermore, recent
reports have indicated the sparse existence of pluripotent
cells among MSCs [37, 38], which expands the possibilities
fortheuseofpluripotentcellsincelltransplantationtherapy.
However,littleisknownaboutthemechanismsandpathways
that control the diﬀerentiation. Further studies are therefore
needed in regard to periodontal regenerative therapy.
3. Characteristicsand Futureof MSC
Because the PDL, bone marrow, adipose, and periosteal tis-
suesarethoughttocontainMSCs,cellsfromthesetissuescan
be used to regenerate mesenchymal tissue, including alve-
olar bone and periodontal ligament. MSCs were ﬁrst iden-
tiﬁed from bone marrow as plastic-adherent ﬁbroblastic cells
and shown to possess a multipotency to diﬀerentiate into
multiple mesenchymal lineages, such as osteocytes, chon-
drocytes, and adipocytes [39, 40]. As early as 1995, MSCs
from multiple sources were transplanted into patients be-
cause of their proliferative property, immunomodulatory,
and trophic eﬀects [41].
Cells extracted enzymatically from tissue tend to possess
proliferative capacities and multipotency. In the dental ﬁeld,
the multipotency of dental pulp cells was ﬁrst described by
Gronthos et al. [42]. This group introduced a method for
digesting tissue with enzymes that dramatically expanded
stem cell research in the dental ﬁeld. Compared to conven-
tional outgrowth methods, enzyme treatment allows for the
harvest of a variety of cell types, such as ﬁbroblastic cells,
vascular cells, and nerve cells, among others [42]. Further-
more, the characteristics of these cells have been shown to
become homogenised during cultivation.
For clinical considerations, each type of MSC has advan-
tages and disadvantages. PDL-MSCs have been shown to ex-
hibit a greater regenerative capacity for PDL tissue compared
to BM-MSCs and periosteal cells in canine one wall defect,
model for severe periodontal defect [13]. Because clinicians
routinely extract teeth, autologous PDL-MSCs can easily be
obtained from patients. However, PDL-MSCs cannot be ap-
plied to patients who lack teeth to be extracted. Periosteal
cells are more easily and abundantly harvested than PDL-
MSCs and BM-MSCs, although periosteal cells require a
longer culture period to obtain a suﬃcient number of cells
for transplantation as compared to PDL-MSCs [17, 43].
BM-MSCs have been transplanted into many patients in
various clinical studies and are thought to be suitable for cell
transplantation therapy due to their multipotency and high
cellular proliferation rate. However, the collection of bone
marrow requires patients hospitalised. Although there are
many data from animals and cells study, there is not enough
clinical data to compare the eﬃcacy of each type of MSC and
theeﬃcacyonsevereperiodontaldefectincludinghorizontal
defect. Thus, it is currently diﬃcult to draw conclusions
about which MSC is most suitable for human periodontal
regenerative therapy.
Recent studies have revealed that MSCs can be extracted
from other tissues. One group of researchers demonstrated
that MSCs are localised in the perivascular compartment
[44]. Park et al. reported that PDL-MSCs could also be ob-
tainedfrominﬂamedPDLtissue[45].BecauseinﬂamedPDL
tissue can be collected during periodontal treatment, it is
possible that this technology will broaden the range of indi-
cations for cell transplantation therapy using PDL-MSCs.
4. Guaranteesof Safety and Efﬁcacy for Stem
CellTransplantationTherapy
Stem cell transplantation therapy is a promising technology
that can regenerate periodontal tissue. However, the eﬃcacy
and safety of cell transplantation therapies are not well
understood. There have been several clinical reports and
reviews published that describe the risks and side eﬀects of
stem cell therapies. To protect patients from such risks, regu-
latory bodies in several countries have begun to establish
guidelines and regulations for the control of stem cell thera-
pies. Therefore, it is imperative that clinicians who aim to
undertake stem cell therapies understand the associated risks
and regulations. In the following section, we provide an
overview of the risks related to stem cell therapies and then
describe our work on a clinical study that was approved by
the regulatory authorities of the Japanese government.
5. Risks of Stem CellTransplantationTherapy
Many scientists suppose and indicate the risks of stem cell
transplantation [46–48] .I n d e e d ,s e v e r es i d ee ﬀects from
stem cell therapies have been reported. One major concern
about stem cell transplantation therapy is the tumorigenic
property of the stem cells themselves. Notably, the formation
of a transplanted cell-derived brain tumour in a patient who
received neural stem cell transplantation was reported [49],
although the precise mechanisms responsible for the forma-
tion of this tumour remain unclear. For MSC-based trans-
plantation, no tumour formation has been reported during
the course of clinical studies involving periodontal cell thera-
pies [46,50]. However, because thetumorigenic potentials of
cells are thought to vary by cell type and application site, the
risk of tumour formation must be investigated in the context
of each type of cell transplantation therapy.
Other risks associated with stem cell transplantation
therapy have been suggested, including those associated with
cell harvesting, cell culture, the site of administration, and
the interaction between the transplanted cells and the reci-
pient’s immune system [48, 51]. Because stem cell trans-
plantation therapy is a new type of treatment, there are few
published data on the fate of stem cells after transplantation.
Therefore, it is important to conﬁrm the safety of these
approaches before applying them to patients, and all data
related to the clinical course of each cell transplantation
therapy should be recorded. As a result, these strategies
should help to reduce patient risk.4 International Journal of Dentistry
6.GovernmentalControloverCell
TransplantationTherapy
Inrecentyears,manynewcelltherapieshavebeendeveloped,
and their numbers continue to grow. However, there are
many cell therapies that are inadequately designed, lacking
evidences of eﬃcacy, safety, and patient protection. For the
protection of patients from such cell therapies, the governing
bodies of Japan, the European Union, and the United States
have been establishing regulations over the control of the
quality of cell transplantation therapies based on Good
Clinical Practice (GCP) and Good Manufacturing Practice
(GMP).
GCPisaninternationalethicalandscientiﬁcqualitystan-
dard that applies to clinical studies and governs their design
and patient protection [52]. According to GCP, data and
plans, including the evidence, potential risks and beneﬁts of
the cell transplantation therapy, the protection of patients’
rights, the scientiﬁc propriety of the protocol, and data man-
agement, must be approved by the institutional review board
and independent ethics committee. GMP governs the cell
culture processes for cell transplantation therapy [53]. GMP
requires that the materials, protocols, tools, and environ-
ments used for cell transplantation therapy are guaranteed as
safe and eﬀective. GMP also requires a record of all cell cul-
ture procedures to be kept in the laboratory for traceability.
Conforming to these regulations requires signiﬁcant
amounts of work and carries a high cost [54]. Cell transplan-
tationtherapyundersuchregulationsareoftentooexpensive
and too late for patients who are in critical need. Therefore,
existing mainstream regulations are sometimes criticised as
overly strict and repressive. Indeed, patients who wish to
receive cell transplantation therapy have been known to
travel to countries where little or no regulation of these pro-
cedures is required to receive the therapy; this is referred
to as “stem cell tourism” [54–56]. However, the safety and
eﬃcacy of many of these therapies have either been ques-
tionedorentirelyinvalidated.Severalsuchcelltherapieshave
been shown to exhibit no eﬀect, and several patients have
died from diseases or complications resulting from the cell
transplantations [55, 57–61]. It is therefore important for
clinicians to implement cell transplantation therapies only
after their eﬃcacy and safety have been validated.
7. Preparationfor ClinicalTrial
Our clinical study of periodontal regenerative therapy using
cell sheet technology has been prepared according to the
guidelines of the Japanese Ministry of Health, Labour, and
Welfare. As we previously demonstrated that PDL cell sheets
were eﬀective for periodontal tissue regeneration in animal
models [9, 11, 62], we have prepared for clinical trial with
thistransferapproach.Themethodsofautologouscelltrans-
plantation and cell culture with autologous serum were
selected to avoid potential infections from animals or other
people. To reduce the risk of tumour formation and to en-
hance hard tissue formation, the cells were cultured in med-
ium that promoted osteoblastic diﬀerentiation after they had
been seeded onto temperature-responsive culture dishes.
We optimised a protocol for harvesting human PDL cells
that would retain their proliferative, osteogenic, and multi-
potency [43]. Regarding the validation of the quality of the
cell sheets, we found that periostin and alkaline phosphatase
(ALP) could be used as quality-control markers of PDL and
osteoblast diﬀerentiation, respectively [43]. Next, using a
canine model for a preclinical study, we investigated the per-
iodontal regenerative capacity of cell sheets that were pre-
pared according to this protocol. The results indicated that
the combined use of autologous PDL cell sheets and β-tri-
calcium phosphate was able to regenerate alveolar bone and
periodontal ligament tissue at defective sites [12].
We alsoestablishedacultureprotocol forthe preparation
of cell sheets that can be applied to patients. PDL cell culture
was performed in a clean suite known as the Cell Processing
Center (CPC). The CPC is composed of several rooms with
controlled air ﬂow in addition to separated personnel and
material line of ﬂow to maintain the cleanliness of the room
and to prevent any possible contamination between person-
nel and cells [63]. All of the work in the CPC was carried
out according to the Standard Operating Procedure (SOP), a
cell culture working protocol that ensures the quality of the
cell sheets. The work in the CPC was always performed by
2 individuals; one performed the culture procedures and the
other directed the procedures to avoid human error and to
keep a record of all of the procedures (Figure 2)[ 63].
After establishing this SOP, we investigated the safety of
the cell sheets that were prepared in this manner. We demon-
strated that the cell sheets were free of contamination by
bacteria or mycoplasma [25]. Because several studies had
indicated that transformation of cells occurred during cul-
ture [64, 65], both in vitro and in vivo tumorigenicity tests
were carried out [25]. Karyotype testing revealed that no
chromosomal abnormalities related to tumorigenicity or
other diseases had occurred in the cultured human PDL
cells (Figure 3). By the soft agar test, cells from the PDL cell
sheets exhibited no evidence of tumorigenic potential in
vitro. Furthermore, the injection of cells isolated from PDL
cellsheetsintoimmunodeﬁcientmicecausednotumourfor-
mation, whereas the injection of cancer cells reliably caused
tumours to form (Figure 4)[ 25].
Next, we conﬁrmed the in vivo and in vitro regenerative
propertiesofthecellsheetsthathadbeenpreparedaccording
the SOP. For in vitro analysis, the cell sheets were found to be
composed of adequate numbers of living cells that expressed
periostinandALP[25].Wethentransplantedcellsheetswith
dentin blocks into immunodeﬁcient mice and conﬁrmed the
formation of PDL- and cementum-like tissue around the
dentin block (Figure 4)[ 25]. We also prepared a document
that contained a full record of these procedures and the
resulting data for submission to the Japanese Ministry of
Health, Labour, and Welfare. This clinical study of PDL cell
sheet transplantation was approved in January 2011.
As previously mentioned, the generation of cell trans-
plantation materials according to the speciﬁed regulations is
an enormously expensive and time-consuming process. For
example, the CPC cost 2 million US dollars to build and
15,000US dollars per year to maintain [63]. The perfor-
mance of the safety and eﬃcacy tests and the preparation ofInternational Journal of Dentistry 5
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Figure 2: CPC of Tokyo Women’s Medical University. (a) Individuals who work in the CPC wear sterile clothing, gloves, caps, and masks to
avoid releasing possible contaminants. (b) All tubes and dishes were labelled to avoid misidentiﬁcation.
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Figure 3: Karyotype of cultured human PDL cells. (a) G-banding staining revealed that the number, banding, and shape of the chromosomes
were normal. (b) Multiplex ﬂuorescence in situ hybridization (M-FISH) that visualises each chromosome in a diﬀerent colour showed that
no chromosomal aberrations, including translocation, had occurred.
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Figure 4: Tumorigenic and regenerative properties of human PDL cell sheets. (a)–(c) Tumorigenesis in vivo. Immunodeﬁcient mice were
injected with medium only (negative control), human PDL cells, or HeLa S3 cells (positive control). Mice injected with human PDL cells or
the medium control did not form tumour-like tissue (a, b), whereas mice injected with HeLa S3 cells exhibited tumour formation (c). (d)–
(f) Histology and immunohistochemistry of implanted human PDL cell sheets with dentin blocks. Newly formed cementum- (arrow) and
PDL-like tissue (arrowheads) were observed around the dentin blocks (d, e). Immunostaining with an antibody against human vimentin
revealed the presence of human PDL cells around the dentin block (f). Scale bars: 500μmi n( a )a n d( b ) ;1m mi n( c ) ;5 0μmi n( d ) – ( f ) .
Modiﬁed from [25] with permission.6 International Journal of Dentistry
the necessary paperwork also represent signiﬁcant burdens
forthecliniciansandassociateduniversitystaﬀ.Nevertheless,
we believe that governmentally regulated cell transplantation
therapy remains the best option for patients. One clinical
solution may be the formation of collaborations between
academic medical centres with existing CPCs. In this way,
the outside clinician would collect tissue from a patient and
send it to the university, where the cells could be harvested
and cultured in a CPC and then sent back to the clinician
for the cell transplantation therapy. For this purpose, Nozaki
etal.developedaspecialcontainercapableofmaintainingan
internaltemperatureof37◦Cformorethan30hourswithout
a power supply. Using this container, cell sheets could
be harvested without losing viability after 8 hours of trans-
portation [66]. Another solution may be the use of closed or
automated cell culture systems. There are several GMP-com-
pliant automated cell culture systems currently available.
Althoughthenecessaryequipmentisexpensive,thetotalcost
would probably be far less than that of building and main-
taining a CPC.
8. Conclusion
In this paper, we have provided an overview of the state of
periodontal regenerative therapy using stem cells. Many pa-
tients suﬀer from periodontitis, and clinicians have struggled
to regenerate the lost alveolar bone. Stem cell therapy is a
promisingnascenttherapythatmayallowtheregenerationof
lost periodontal tissue. Although there are many issues that
need to be resolved before stem cell therapies become com-
mon, clinicians should continue to keep a watchful eye on
the progression.
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